Dogwood Therapeutics (DWTX) Income from Continuing Operations (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Income from Continuing Operations of 107753.0 for Q1 2026, up 99.0% year-over-year from 54148.27 in Q1 2025, and up 99.67% quarter-over-quarter from 32452522.0 in Q4 2025.
Dogwood Therapeutics (DWTX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Income from Continuing Operations for 7 consecutive years, with 107753.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 99.0% year-over-year to 107753.0; the TTM figure through Mar 2026 stood at 36785261.0 (down 68.79% YoY), while the FY2025 annual figure was 34036274.0, down 175.59% from the prior year.
- Income from Continuing Operations improved to 107753.0 in Q1 2026 per DWTX's latest filing, from 32452522.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 107753.0 in Q1 2026 and bottomed at 32452522.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 4553749.82 across 5 years, with a median of 2044556.0 in 2022.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations sank 731.26% — and 2026, when it surged 99.0%.
- Dogwood Therapeutics' Income from Continuing Operations stood at 2044556.0 in 2022, then jumped by 46.04% to 1103173.0 in 2023, then sank by 600.56% to 7728375.0 in 2024, then tumbled by 319.91% to 32452522.0 in 2025, then surged by 99.67% to 107753.0 in 2026.
- Business Quant data shows DWTX's Income from Continuing Operations at 107753.0 in Q1 2026, 32452522.0 in Q4 2025, and 417782.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - | -14.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -107,753.00 |
| Dec 31, 2025 | -32.45 Mn |
| Sep 30, 2025 | -417,782.00 |
| Jun 30, 2025 | -3.81 Mn |
| Mar 31, 2025 | -10.73 Mn |
| Dec 31, 2024 | -7.73 Mn |
| Sep 30, 2024 | -2.28 Mn |
| Jun 30, 2024 | -1.05 Mn |
| Mar 31, 2024 | -1.29 Mn |
| Dec 31, 2023 | -1.10 Mn |
| Sep 30, 2023 | -1.24 Mn |
| Jun 30, 2023 | -1.44 Mn |
| Mar 31, 2023 | -1.52 Mn |
| Dec 31, 2022 | -2.04 Mn |
| Sep 30, 2022 | -2.58 Mn |
| Jun 30, 2022 | -3.67 Mn |
| Mar 31, 2022 | -3.96 Mn |
| Dec 31, 2021 | -4.51 Mn |
| Sep 30, 2021 | -4.11 Mn |
| Jun 30, 2021 | -4.28 Mn |